TriangleBiopsy Procedure (NCT06980077)
Biopsy Procedure trial for Thymus Carcinoma (NCT06980077). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with incurable thymic carcinoma after systemic treatment, or when other therapies are unsuitable or declined. Prior PD-1 or PD-L1 checkpoint treatment is excluded. Autoimmune and paraneoplastic-antibody screening rules apply.
The idea: use ivonescimab, an antibody that targets both PD-1 immune suppression and VEGF-driven blood-vessel growth. Infusions are given every three weeks for up to two years unless progression or unacceptable toxicity occurs. Researchers assess tumor responses and safety. An end-of-treatment biopsy is optional.
This phase 2 study plans 25 patients. UCLA's Jonathan Goldman leads two recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.